Celgene expands Dragonfly NK cells pact to the tune of $50M

Dragonfly’s pipeline is based on its TriNKET, or Tri-specific, NK cell Engager Therapeutics, which bind to surface proteins expressed on both cancer cells and NK cells. (Pixabay)

Celgene is doubling down on its cancer immunotherapy pact with Dragonfly Therapeutics, paying $50 million up front for access to four more natural killer (NK) cell-based programs. The pair initially tied up in June 2017, when Celgene forked over $33 million for the option to license four assets aimed at the treatment of blood cancers.

The original four assets are designed to treat acute myeloid leukemia, multiple myeloma and other hematological cancers, while the new four include treatments in development for solid tumors, Cambridge, Massachusetts-based Dragonfly said in a statement.

If Celgene pulls the trigger on any of its now eight options, it will be on the hook for potential milestone and royalty payments, as well as “other material considerations.”

Sponsored by Biotech Primer

September 2-3, 2020 Live, Online Course: Biopharma Revenue Forecasting that Drives Decision Making and Investments

Become fluent in the core elements of revenue forecasting including epidemiology, competitive assessments, market share assignment and pricing. Let Biotech Primer's dynamic industry experts teach you how to assess the value of new therapies.

RELATED: Celgene bags option on NK cell-based blood cancer assets

Dragonfly’s pipeline is based on its TriNKET, or Tri-specific, NK cell Engager Therapeutics, which bind to surface proteins expressed on both cancer cells and NK cells. This alerts the NK cells to the cancer; they then directly attack the tumor while also recruiting other immune cells to join in. T cells, the basis of many current immuno-oncology approaches, then directly attack the tumor, while B cells produce antibodies to help the fight against the cancer. 

The company’s pipeline is still preclinical, but the approach caught Celgene’s eye last year as an “increasingly critical” area of hematologic research, as Rupert Vessey, Celgene’s president of research and early development, said at the time.

And it looks like the technology has been delivering: "We have watched the field of NK-cell biology and immunotherapy evolve considerably since entering our initial collaboration with Dragonfly and are pleased to expand our access to their novel therapeutic candidates," Vessey said in the statement. 

RELATED: Skyhawk, copying Dragonfly model, gets cash for RNA R&D

"Based on the evidence we've seen to date, we believe that Dragonfly's novel TriNKET technology provides a unique platform to support the discovery and development of immunotherapy drug candidates that may help cancer patients, with potential both as monotherapy and in combination with existing therapeutics."

The expanded deal with Celgene comes about six weeks after Dragonfly inked a multi-target solid tumor pact with Merck that could be worth $695 million per program.

Editor's note: This story was updated to clarify that Dragonfly could pick up $695 million in upfront and milestone payments per target in its multi-target deal with Merck.

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.